- Home
- TNON vs BOLT Comparison
TNON vs BOLT Comparison
Compare TNON & BOLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TNON | BOLT |
|---|---|---|
| Founded | 2012 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.6M | 10.5M |
| IPO Year | 2022 | 2021 |
Fundamental Metrics
Financial Performance| Metric | TNON | BOLT |
|---|---|---|
| Price | $0.98 | $6.25 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 4 |
| Target Price | $3.00 | ★ $34.00 |
| AVG Volume (30 Days) | ★ 77.5K | 28.7K |
| Earning Date | 11-13-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $3,233,000.00 | ★ $5,195,000.00 |
| Revenue This Year | $19.56 | N/A |
| Revenue Next Year | $71.06 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.85 | $4.41 |
| 52 Week High | $5.85 | $11.70 |
Technical Indicators
Market Signals| Indicator | TNON | BOLT |
|---|---|---|
| Relative Strength Index (RSI) | 44.72 | 60.54 |
| Support Level | $0.94 | $5.61 |
| Resistance Level | $1.03 | $6.09 |
| Average True Range (ATR) | 0.05 | 0.41 |
| MACD | 0.00 | 0.10 |
| Stochastic Oscillator | 39.07 | 59.42 |
Price Performance
Historical ComparisonAbout TNON Tenon Medical Inc.
Tenon Medical Inc is a medical device company that has developed a novel, minimally invasive approach to the sacroiliac joint (the SI Joint) using a single, robust, titanium implant for the treatment of the common types of SI Joint disorders that cause lower back pain. The Company is focused on three commercial opportunities; Primary SI Joint procedures, Revision procedures of failed SI Joint implants, and SI Joint fusion adjunct to a spine fusion construct. The company derives the majority of its revenue from sales of The Catamaran System to a limited number of clinicians.
About BOLT Bolt Biotherapeutics Inc.
Bolt Biotherapeutics Inc is a clinical-stage immuno-oncology company. It is developing tumor-targeted therapies that leverage the power of the innate and adaptive immune systems. The company's pipeline candidates are built on deep expertise in myeloid biology and cancer drug development. The company's proprietary Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. The company's pipeline consists of BDC-1001, BDC-3042, and Next-Gen ISAC.